|
![]() |
![]() ![]() |
![]() |
|
||
![]() |
![]() |
Re: Merck to Acquire Immune Designread this as well. This is a very intriguing move from $MRK. After NY-ESO-1 based CMB305 failed Tecentriq combo in synovial sarcoma, $IMDZ decided to focus on G100 intratumoral TLR4 agonist for NHL. So clearly $MRK IS interested in activating DCs via TLR pathway AND intratumoral delivery route (also with its own STING agonist). However, TLR4, IMHO, is a mediocre TLR target comparing with CpG-TLR9. 1. TLR4 is on cell surface, TLR9 is in the endosome 2. TLR4 is less APC specific, TLR9 is DC specific. 3. TLR4 is a poor interferon inducer, TLR9 is excellent IFN inducer. The first two points will lead to toxicity, and the last point may suggest inferior efficacy. For whatever reason, $MRK decided to buy $IMDZ. The chance of a deal with $DVAX? Will $MRK partner up with another TLR company? Let's see.
|
![]() ![]() ![]() ![]() |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
1514 | Re: Merck to Acquire Immune Design | smittyfrmpa | 0 | 2/22/2019 11:41:42 AM |